Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MYMDNASDAQ:PTPINASDAQ:QLGNNASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMYMDMyMD Pharmaceuticals$0.14-6.7%$0.19$1.75▼$63.90$331K2.15134,123 shs1.84 million shsPTPIPetros Pharmaceuticals$0.03-10.0%$0.36$0.02▼$16.25$841K1.573.13 million shs478,145 shsQLGNQualigen Therapeutics$3.74+6.6%$3.65$2.85▼$29.44$2.75M0.01111,328 shs73,350 shsTHARTharimmune$1.43-0.7%$1.40$0.95▼$6.39$3.80M1.04371,885 shs5,412 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMYMDMyMD Pharmaceuticals0.00%-17.09%-22.71%-62.38%-93.08%PTPIPetros Pharmaceuticals-10.00%-10.00%-79.56%-98.58%-99.73%QLGNQualigen Therapeutics+6.55%-1.58%-1.32%+20.26%-60.00%THARTharimmune-0.69%-8.92%-0.25%-7.74%-51.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APTPIPetros Pharmaceuticals0.3285 of 5 stars0.03.00.00.00.60.80.6QLGNQualigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATHARTharimmune2.2112 of 5 stars3.85.00.00.00.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMYMDMyMD Pharmaceuticals 0.00N/AN/AN/APTPIPetros Pharmaceuticals 0.00N/AN/AN/AQLGNQualigen Therapeutics 0.00N/AN/AN/ATHARTharimmune 3.50Strong Buy$17.001,088.81% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMYMDMyMD PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/APTPIPetros Pharmaceuticals$5.11M0.16N/AN/A$4.04 per share0.01QLGNQualigen Therapeutics$4.98M0.56N/AN/A($20.31) per share-0.18THARTharimmuneN/AN/AN/AN/A$0.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMYMDMyMD Pharmaceuticals-$4MN/A0.00∞N/AN/A-179.05%-108.14%N/APTPIPetros Pharmaceuticals-$8.16M-$119.00N/A∞N/AN/A-78.22%-23.50%N/AQLGNQualigen Therapeutics-$13.42MN/A0.00∞N/AN/AN/A-424.18%7/1/2025 (Estimated)THARTharimmune-$12.20M-$7.88N/A∞N/AN/A-489.33%-264.34%N/ALatest MYMD, PTPI, THAR, and QLGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PTPIPetros PharmaceuticalsN/A-$8.46N/A-$9.37N/AN/A5/12/2025Q1 2025THARTharimmune-$0.84-$0.99-$0.15-$0.99N/AN/A3/25/2025Q4 2024THARTharimmuneN/A-$2.02N/A-$2.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMYMDMyMD PharmaceuticalsN/A0.620.62PTPIPetros Pharmaceuticals1.580.850.74QLGNQualigen TherapeuticsN/A0.520.52THARTharimmuneN/A0.670.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMYMDMyMD Pharmaceuticals9.64%PTPIPetros Pharmaceuticals12.34%QLGNQualigen Therapeutics3.18%THARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipMYMDMyMD Pharmaceuticals2.12%PTPIPetros Pharmaceuticals12.25%QLGNQualigen Therapeutics1.80%THARTharimmune10.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMYMDMyMD Pharmaceuticals62.37 million2.32 millionOptionablePTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableQLGNQualigen Therapeutics50740,000723,000Not OptionableTHARTharimmune22.66 million2.40 millionNot OptionableMYMD, PTPI, THAR, and QLGN HeadlinesRecent News About These CompaniesTharimmune CFO Don Kim ResignsJune 17 at 10:44 AM | marketwatch.comTharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of DirectorsJune 17 at 8:01 AM | accessnewswire.comTharimmune announces executive changes and new agreementsJune 13, 2025 | investing.comTharimmune advances opioid prophylaxis drug TH104May 7, 2025 | investing.comTharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA FeedbackMay 6, 2025 | accessnewswire.comTharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL ConferencesMay 1, 2025 | accessnewswire.comTharimmune Appoints Clay Kahler and Gary Stetz to its Board of DirectorsApril 30, 2025 | accessnewswire.comTharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA FeedbackApril 28, 2025 | sacbee.comTharimmune announces board retirements ahead of annual meetingApril 26, 2025 | investing.comTharimmune Inc.: Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of DirectorsApril 15, 2025 | finanznachrichten.deTharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of DirectorsApril 15, 2025 | accessnewswire.comTharimmune reports data on new biparatopic biologicsApril 9, 2025 | bioworld.comTharimmune announces preclinical data from expanded pipeline with HS1940April 9, 2025 | markets.businessinsider.comTharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) TechnologyApril 7, 2025 | accessnewswire.comTharimmune receives Nasdaq non-compliance noticeApril 6, 2025 | investing.comTharimmune announces FDA feedback on NDA path for TH104April 1, 2025 | markets.businessinsider.comTharimmune announces FDA feedback on TH104 NDA pathApril 1, 2025 | markets.businessinsider.comTharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid ExposureMarch 31, 2025 | accessnewswire.comTharimmune announce preclinical TH023 resultsMarch 25, 2025 | markets.businessinsider.comTharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alphaMarch 24, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYMD, PTPI, THAR, and QLGN Company DescriptionsMyMD Pharmaceuticals NASDAQ:MYMD$0.14 -0.01 (-6.68%) As of 06/18/2025MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Petros Pharmaceuticals NASDAQ:PTPI$0.03 0.00 (-10.00%) As of 06/18/2025 03:05 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.Qualigen Therapeutics NASDAQ:QLGN$3.75 +0.24 (+6.95%) As of 06/18/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Tharimmune NASDAQ:THAR$1.43 -0.01 (-0.69%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.45 +0.02 (+1.40%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
